As alluded to in another thread, there is a much larger P3 trial requirement. A second trial that will run in conjunction with the first. Over 1,000 participants in total.
Primary and Secondary end points have been agreed to.
WOMAC scores for SAS patients have been published.
I don't think there is any funny business here - FDA minutes were provided to PAR, dictated a larger trial requirement, PAR want to make sure they are covered for the larger trial and OPEX for 2 years.
As alluded to in another thread, there is a much larger P3 trial...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $116.0K | 491.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 33682 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |